根治性治疗前列腺癌患者穿刺活检细胞周期进展(CCP)评分预后效用分析
该汇总分析纳入四家机构1062例接受根治性前列腺切除术或放疗的局限性前列腺癌患者,用活检组织46个基因RNA表达计算CCP评分及CCR评分。多变量分析中CCP评分与10年转移风险独立相关(HR 2.21),CCR评分预后价值更高(HR 4.00),两评分与队列和治疗类型均无交互作用。
要点
- CCP评分每增加1单位,10年转移风险HR为2.21(95%CI 1.64-2.98)。
- CCR评分每增加1单位,10年转移风险HR为4.00(95%CI 2.95-5.42)。
- CCP和CCR与队列及治疗类型均无交互作用。
核心结论
- CCP和CCR评分在手术和放疗后均提供预测转移的独立预后信息,进一步显示其作为新诊断前列腺癌风险分层工具的潜在用途。
研究设计与样本
- 汇总分析纳入四家机构(Martini Clinic、Durham VA Medical Center、Intermountain Healthcare、Ochsner Clinic)共1062例接受根治性前列腺切除术或放疗(近距离放疗或外照射放疗±激素治疗)的局限性前列腺癌患者。
- CCP评分基于石蜡包埋活检组织中46个基因的RNA表达确定,CCR评分由CCP评分与CAPRA评分的预设线性组合计算。
主要发现
- 调整CAPRA、治疗类型和队列后,CCP评分与10年转移风险在多变量分析中强相关:HR 2.21(95%CI 1.64-2.98;p=1.9×10⁻⁶)。
- CCR评分同样具有高度预后价值:HR 4.00(95%CI 2.95-5.42;p=6.3×10⁻²¹)。
- CCP或CCR与队列无交互作用证据(p=0.79和p=0.86),与治疗类型亦无交互作用证据(p=0.55和p=0.78)。
- 基于CCR的10年转移预测风险范围为0.1%至99.4%(IQR 0.7%-4.6%)。
临床怎么用
- 作者认为CCP和CCR评分有潜力作为新诊断前列腺癌患者的风险分层工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate risk stratification can help guide appropriate treatment decisions in men with localized prostate cancer. Here, we evaluated the independent ability of the molecular cell cycle progression (CCP) score and the combined cell-cycle clinical risk (CCR) score to predict 10-year risk of progression to metastatic disease in a large, pooled analysis of men with definitively treated prostate cancer. METHODS: The pooled analysis included 1,062 patients from four institutions (Martini Clinic, Durham VA Medical Center, Intermountain Healthcare, Ochsner Clinic) treated definitively for localized prostate cancer by either radical prostatectomy or radiotherapy (brachytherapy or external beam radiotherapy ± hormone therapy). The CCP score was determined using the RNA expression of 46 genes from archival formalin-fixed paraffin-embedded biopsy tissue. The CCR score was calculated using a predefined linear combination of the CCP score and the Cancer of the Prostate Risk Assessment (CAPRA) score. The scores were evaluated for association with 10-year risk of metastatic disease following definitive therapy after adjusting for other clinical variables. RESULTS: The CCP score was strongly associated with 10-year risk of metastatic disease in multivariable analysis [Hazard Ratio per unit score = 2.21; 95% confidence interval (CI) 1.64, 2.98; p = 1.9 × 10-6] after adjusting for CAPRA, treatment type, and cohort. CCR was also highly prognostic (Hazard Ratio per unit score = 4.00; 95% CI 2.95, 5.42; p = 6.3 × 10-21). There was no evidence of interaction between CCP or CCR and cohort (p = 0.79 and p = 0.86, respectively) or treatment type (p = 0.55 and p = 0.78, respectively). Observed patient CCR-based predicted risks for metastatic disease by 10 years ranged from 0.1 to 99.4%, (IQR 0.7%, 4.6%). CONCLUSIONS: Both CCP and CCR scores provided independent prognostic information for predicting progression to metastatic disease after both surgery and radiation. These results further demonstrate their potential use as a risk stratification tool in patients with newly-diagnosed prostate cancer.
引用
- Canter DJ, Freedland S, Rajamani S, et al. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate Cancer Prostatic Dis. 2019. PMID: 31243337. doi:10.1038/s41391-019-0159-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。